CD274 and melanoma: In previously treated patients, ICB has demonstrated encouraging 5-year overall survival (OS) rates, reaching 34% in melanoma, 28% in RCC, and 16% in NSCLC, leading to approval of anti-PD-1, anti-PD-L1, and anti-Cytotoxic T Lymphocyte Antigen 4 inhibitor (anti-CTLA4) for its use in the metastatic setting across several malignancies [37].